Neurobo pharmaceuticals, inc. (GEMP)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
Operating expenses:
Research and development

2,152

1,222

1,068

1,234

1,800

1,833

3,542

3,960

4,977

5,080

6,489

5,837

5,280

4,839

1,936

789

1,176

1,464

1,369

952

206

Acquired in‑process research and development

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

908

General and administrative

2,597

-315

1,250

1,115

651

1,468

2,364

2,574

2,087

1,487

2,050

4,678

2,223

2,389

1,466

1,051

1,050

1,047

997

658

475

Total operating expenses

4,749

13,058

2,318

2,349

2,451

3,301

5,906

6,534

7,064

6,567

8,539

10,515

7,503

7,228

3,402

1,840

2,226

2,511

2,366

1,610

1,589

Loss from operations

-4,749

-13,058

-2,318

-2,349

-2,451

-3,301

-5,906

-6,534

-7,064

-6,567

-8,539

-10,515

-7,503

-7,228

-3,402

-1,840

-2,226

-2,511

-2,366

-1,610

-1,589

Interest (expense) income, net

20

-23

4

10

-13

-178

-172

-144

-160

-179

-132

13

12

13

-475

449

127

137

-209

0

-690

Loss on note extinguishment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-198

-

-

-

Other income (expense), net

-1

-

-1,116

-581

-

-177

-1

-

-

0

0

0

-5

1

-1

0

-4

2

6

-1

-

Loss before income taxes

-4,730

-12,498

-3,430

-2,920

-2,464

-3,656

-6,079

-6,678

-7,224

-6,746

-8,671

-10,502

-7,496

-7,214

-3,878

-1,391

-2,103

-2,570

-2,569

-1,611

-2,279

Provision for income taxes

0

0

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-4,730

-12,498

-3,430

-2,920

-2,464

-3,656

-6,079

-6,678

-7,224

-6,746

-8,671

-10,502

-7,496

-7,214

-3,878

-1,391

-2,103

-2,570

-2,569

-1,611

-2,279

Other comprehensive loss:
Foreign currency translation loss, net of tax

-34

-

-

-

-2

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total other comprehensive loss

-34

12

0

0

-2

2

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Comprehensive loss

-4,764

-12,486

-3,430

-2,920

-2,466

-3,656

-6,079

-6,678

-7,224

-6,746

-8,671

-10,502

-7,496

-7,214

-3,878

-1,391

-2,103

-2,570

-2,569

-1,611

-2,279

Net loss

-4,730

-12,498

-3,430

-2,920

-2,464

-3,656

-6,079

-6,678

-7,224

-6,746

-8,671

-10,502

-7,496

-7,214

-3,878

-1,391

-2,103

-2,570

-2,569

-1,611

-2,279

Adjustment to redemption value on Series A convertible preferred stock

-

-

-

-

-

-

-

-

-

0

0

0

0

0

67

150

149

150

152

149

2,517

Premium upon substantial modification of convertible note with certain shareholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,047

-

-

-

Net loss attributable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-7,214

-3,945

-1,541

-2,252

-3,767

-2,721

-1,760

-4,796

Loss per share:
Net loss per share, basic and diluted (Note 11)

-0.30

-3.16

-0.24

-0.20

-0.48

-0.26

-0.43

-0.47

-0.58

-

-

-

-

0.78

0.56

0.42

0.65

-1.14

-0.87

-0.60

-2.27

Weighted average common shares outstanding:
Basic and diluted

15,670

-12,800

14,265

14,265

5,166

-23,926

14,259

14,232

12,439

-

-

-

-

-

-

-

-

-

-

-

-